These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Changes in the prostatic cancer cells caused by estrogen therapy--cytological study by aspiration biopsy]. Takeuchi H Gan No Rinsho; 1971; 17(9):692-9. PubMed ID: 5165863 [No Abstract] [Full Text] [Related]
5. DNA grading of malignancy and tumor regression in prostatic carcinoma under hormone therapy. Böcking A; Auffermann W; Jocham D; Contractor H; Wohltmann D Appl Pathol; 1985; 3(4):206-14. PubMed ID: 3842263 [TBL] [Abstract][Full Text] [Related]
6. [The prognostic significance of cytologic differentiation grades of estrogen-treated prostata carcinoma. Progress control of 496 prostate carcinoma patients treated with estrogen for five years (author's transl)]. Faul P; Schmiedt E; Kern R Urologe A; 1978 Nov; 17(6):377-81. PubMed ID: 726160 [TBL] [Abstract][Full Text] [Related]
7. A DNA cytometric proliferation index improves the value of the DNA ploidy pattern as a prognosticating tool in patients with carcinoma of the prostate. Ahlgren G; Lindholm K; Falkmer U; Abrahamsson PA Urology; 1997 Sep; 50(3):379-84. PubMed ID: 9301701 [TBL] [Abstract][Full Text] [Related]
8. DNA image cytometry of prostatic carcinoma: a comparison of needle core biopsy and subsequent prostatectomy specimens. Leung CS; Zbieranowski I; Demers J; Murray D Mod Pathol; 1994 Feb; 7(2):195-9. PubMed ID: 8008743 [TBL] [Abstract][Full Text] [Related]
10. [Flow cytometry in prostate cancer. Evaluation of its feasibility for biopsy specimens and correlation with grading]. Ferrara G; Monaco R; Capasso A; Bellomo PF; Fruttero A; Pugno F; Nappi O; Ruà S Pathologica; 1998 Feb; 90(1):14-9. PubMed ID: 9628974 [TBL] [Abstract][Full Text] [Related]
11. [Cytophotometric and automated cytodiagnosis]. Böcking A Microsc Acta Suppl; 1983; 6():91-102. PubMed ID: 6578409 [TBL] [Abstract][Full Text] [Related]
12. Conventional assessment of needle biopsy specimens is more useful than digital image analysis of proliferation and DNA ploidy in prediction of positive surgical margins at radical prostatectomy. Sengupta S; Cheville JC; Lohse CM; Zincke H; Myers RP; Riehle DL; Pankratz VS; Blute ML; Sebo TJ Urology; 2006 Jul; 68(1):94-8. PubMed ID: 16844452 [TBL] [Abstract][Full Text] [Related]
13. Reproducibility of FCM-DNA ploidy analysis in prostatic cancer: comparison between needle biopsy and surgical specimens. Sassi I; Mangili F; Sanvito F; Andreassi A; Cantaboni A Anal Cell Pathol; 1993 Jan; 5(1):17-21. PubMed ID: 8424898 [TBL] [Abstract][Full Text] [Related]
14. Changes in tissue prostatic acidic phosphatase during endocrine treatment of patients with prostatic carcinoma. Grande M; Carlström K; Lundh-Rozell B; Stege R; Pousette A Scand J Urol Nephrol; 2005; 39(5):393-8. PubMed ID: 16257841 [TBL] [Abstract][Full Text] [Related]
15. Results of the primary treatment in T1-3M0 prostatic adenocarcinoma are dependent on tumour biology. Vesalainen S; Lipponen P; Nordling S; Talja M; Syrjänen K Anticancer Res; 1995; 15(2):569-73. PubMed ID: 7763039 [TBL] [Abstract][Full Text] [Related]
16. [Clinical significance of prostatic cytology and its diagnostic possibilities]. Faul P MMW Munch Med Wochenschr; 1974 Jan; 116(1):15-8. PubMed ID: 4204456 [No Abstract] [Full Text] [Related]
17. Re: Franclim R. Ribeiro, Rui Henrique, Ana T. Martins, Carmen Jerónimo and Manuel R. Teixeira. Relative copy number gain of MYC in diagnostic needle biopsies is an independent prognostic factor for prostate cancer patients. Eur Urol 2007;52:116-25. Cianciulli A; Merola R; Leonardo C Eur Urol; 2007 Nov; 52(5):1538-9; author reply 1539-40. PubMed ID: 17764827 [No Abstract] [Full Text] [Related]